# Extension Study of ABP-671 in Participants With Gout

> **NCT06276556** · PHASE2,PHASE3 · TERMINATED · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 43 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** ABP-671
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT06276556
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-22
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** For business consideration, a new long-term safety study will be conducted in the next new pivotal studies.
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276556, "Extension Study of ABP-671 in Participants With Gout". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06276556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*